RUTW250103P2020000
- 2.76
- 0.000.00%
Russell 2000 Index Newsroom
Global Medical REIT Announces Succession Plan; CEO Transition Expected In 2025; Jeffrey Busch To Remain On Board Of Directors As Non-Executive Chairman; Lori Wittman Appointed Lead Independent Director Effective January 1, 2025
Vanda Pharmaceuticals Pens Letter To FDA Commissioner Regarding Approval For Tradipitant For Treatment Of Patients With Gastroparesis
Greenbrier GAAP EPS of $1.72 Beats by $0.56, Revenue of $875.9M Beats by $26.39M
Earnings Summary: Pricesmart Q1
Avadel Pharmaceuticals Sees Prelim. Q4 Revenue ~$50.0M Vs $52.312M Est.
Earnings Breakdown: Franklin Covey Q1
Franklin Covey GAAP EPS of $0.09 Misses by $0.06, Revenue of $69.09M Misses by $1.06M
Dyne Therapeutics To Release New Clinical Data From Phase 1/2 ACHIEVE Trial On January 10, 2025; Investor Conference Call And Webcast Scheduled For 8:00 AM ET
PriceSmart GAAP EPS of $1.21 Misses by $0.15, Revenue of $1.26B Beats by $20M
10 Information Technology Stocks Moving In Wednesday's Pre-Market Session
12 Consumer Discretionary Stocks Moving In Wednesday's Pre-Market Session
Zymeworks Expects $324M Cash Resources, Plus $25M Milestone, To Fund Operations Into 2H-2027
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Industrials Stocks Moving In Wednesday's Pre-Market Session
Scholar Rock Highlights Upcoming Priorities For 2025; Says BLA And MAA Submission For Apitegromab In SMA On Track For Q1
Simulations Plus Analyst Ratings
Recursion Pharmaceuticals Analyst Ratings
Options Corner: Trade The Ride, Not The Direction Of SoundHound AI
LifeMD Analyst Ratings
Fluor Analyst Ratings